How to Test for Mast Cell Activation Syndrome

Last Updated: May 15, 2026

By: Brian Karr · Co-Founder & Chief Inspection Officer, We Inspect

Testing for mast cell activation syndrome requires collecting specific blood and urine markers during or immediately after a reaction — not days later when levels have normalized. The three core diagnostic markers are serum tryptase, 24-hour urine N-methylhistamine, and 24-hour urine prostaglandins. Most standard workups miss the timing window entirely. Almost none investigate what’s triggering the mast cells in the first place.

Mast cell activation syndrome (MCAS) is a condition in which mast cells, immune cells distributed throughout the body’s tissues, chronically release excessive chemical mediators in response to triggers. Unlike systemic mastocytosis, MCAS does not involve abnormal mast cell proliferation — the cell count is normal, but the behavior is not. Diagnosing it requires catching the mediators those cells release, which means testing at the right moment.

MCAS is one of the hardest conditions to confirm on paper, not because the testing is obscure, but because most clinicians draw labs at the wrong time and check the wrong markers. A tryptase drawn three days after a reaction will look completely normal. So will a histamine level taken without a 24-hour urine collection. The diagnostic criteria have been clearly defined in the peer-reviewed literature since at least 2011.¹ Applying them correctly — with proper timing, proper markers, and a documented baseline — changes what you find. There is also a second gap most practitioners never address: what is activating the mast cells. For a significant number of patients, that answer starts at home.

Table of Contents

• What the MCAS Diagnostic Criteria Actually Require
• Why Timing Is the Biggest Mistake in MCAS Testing
• The Environmental Trigger Nobody Tests For
• What to Ask Your Doctor Before Your Next Appointment
• Can MCAS Improve? What the Evidence Shows

What the MCAS Diagnostic Criteria Actually Require

The consensus diagnostic criteria for MCAS, as established in the peer-reviewed literature, require three things to align.^1,2 First: recurring episodic symptoms involving at least two organ systems — skin, gastrointestinal, cardiovascular, respiratory, or neurological. Second: laboratory evidence that mast cell mediators are genuinely elevated, timed specifically to a symptomatic episode. Third: a positive clinical response to mast cell-targeting treatments such as antihistamines, cromolyn sodium, or mast cell stabilizers.

The second criterion is where nearly every standard workup falls apart.

To meet the mediator threshold, serum tryptase must rise at least 20% above the established baseline plus 2 ng/mL during a symptomatic episode compared to a symptom-free draw.² That calculation requires two tryptase measurements: one during the reaction and a separate baseline collected when the patient is not symptomatic. Most labs run one draw. Most clinicians never document a baseline. Without a baseline, the 20% + 2 rule is mathematically impossible to apply.

I get a version of this call about once a week. A parent — usually a mom — has just gotten an MCAS diagnosis for her child after months of unexplained reactions. The allergist ran a tryptase during a flare, prescribed a second antihistamine, sent them home. Last month it was a family from Denver: their 8-year-old had been reacting since they moved into their new house about two years earlier. “Her symptoms started when we moved in,” the mom told me. “Nobody’s ever asked us about the home.” The environmental question was not on the workup. It rarely is.

The Three Core Mediator Tests

Three specific markers form the diagnostic foundation for MCAS.³ Each has distinct timing requirements and reflects different aspects of mast cell activity:

• 24-hour urine N-methylhistamine (NMH) — the most stable histamine metabolite. Reflects cumulative mast cell release over time rather than a brief serum snapshot, which decays within minutes.
• 24-hour urine 11β-prostaglandin F2α (11β-PGF2α) — a breakdown product of prostaglandin D2, a major mast cell mediator. More clinically reliable than serum prostaglandin D2 because urine collection smooths the decay curve.
• Serum tryptase — when timed correctly, the closest thing MCAS has to a definitive marker. Requires collection within the first few hours of symptom onset and a documented symptom-free baseline for comparison.

Adjunctive markers some clinicians also order include plasma heparin, serum chromogranin A, and urine leukotriene E4. These are supportive rather than primary, and not all labs process them reliably. Start with the three core markers and build from there.

Why Timing Is the Biggest Mistake in MCAS Testing

Tryptase degrades quickly. After a mast cell event, the serum window for catching an elevated result is roughly two to four hours from symptom onset — and that window assumes the reaction was significant enough to cause a detectable spike.⁴ A result drawn the day after a severe reaction will look normal. A result from three days later will definitely look normal. This creates the diagnostic cycle most MCAS patients know well: real, recurring reactions, unremarkable labs, a physician who concludes the symptoms are anxiety or functional.

The 24-hour urine markers — N-methylhistamine and 11β-PGF2α — provide a longer collection window because they measure metabolites accumulating in urine over the course of a day rather than catching a brief serum peak. They still benefit from being collected during a symptomatic period, but the biochemistry is more forgiving.

Here is what a properly structured MCAS workup looks like compared to what most patients actually receive:

The Environmental Trigger Nobody Tests For

Every MCAS workup documents what the patient reacts to. Foods. Medications. Fragrance. Heat. The list can be long and overwhelming. What rarely makes the list is the air they breathe at home for eight or more hours a night.

Mold and mycotoxins are documented mast cell activators. Research has linked volatile organic compounds produced by actively growing mold in water-damaged buildings to inflammatory responses in sensitized individuals.⁵ Specific mycotoxins, including those produced by common indoor mold species like Penicillium, are known to disrupt immune cell signaling at concentrations found in water-damaged buildings.⁶ For patients with heightened mast cell reactivity, sustained low-level exposure can mean a constant state of low-grade activation — a background inflammation that makes every other trigger hit harder than it should.

The pattern shows up on consultation calls more than most people expect. One parent put it exactly right: her daughter had been diagnosed with MCAS, and the symptoms had started when they moved into their house two years earlier. The timing was precise. But the environmental piece had never been part of the diagnostic conversation. Another caller — someone who’d spent months managing his reactions — noticed the same thing: he did better on vacation. Better when he was traveling for work. Better anywhere that wasn’t home. “You start realizing you’re away from the house, and things are better,” he told me. That’s not a coincidence pattern. It’s a data point.

The standard medical workup for MCAS was designed to capture what the body produces in reaction to triggers. It was not designed to find triggers concealed in building materials. A positive mycotoxin urine test tells you exposure is happening — it does not tell you where. Source-level inspection is what identifies the location of active mold growth in the walls, subfloor, or HVAC system and maps it against where the person spends their time.

What to Ask Your Doctor Before Your Next Appointment

If you’re pursuing an MCAS workup — or questioning why a previous one came back clean — these specific questions change what gets ordered and how results get interpreted.⁴

Ask about establishing a tryptase baseline. Request a draw specifically when you are symptom-free, so any reaction-time result has a documented comparison point. Without this, the 20% + 2 diagnostic threshold cannot be calculated.

Ask for a 24-hour urine collection for N-methylhistamine and 11β-prostaglandin F2α. Serum histamine alone is unreliable. These urine metabolites are far more stable and far more likely to reflect what’s actually happening across a full mast cell activation cycle.

Ask whether the practice has a same-day specimen collection protocol during a reaction. If the answer is no, ask how they recommend handling an acute episode. Having a plan — a standing order, an after-hours contact, a clear instruction on when and where to go — means you can act during the narrow serum window rather than arriving the next morning with a normal result.

Ask whether environmental triggers have been evaluated. Specifically: whether sustained exposure to water-damaged building materials could be part of the picture. If you have had a high ERMI result or a positive mycotoxin urine test, bring it to the appointment. An immunologist focused on mediator testing may not connect those dots to a home environment — not from lack of interest, but because environmental trigger mapping is not part of a standard immunology workup.

Can MCAS Improve? What the Evidence Shows

MCAS is not a life sentence. The peer-reviewed literature is consistent on this point: patients who identify and remove their primary triggers — and respond well to mast cell-stabilizing therapy — show meaningful reductions in symptom burden and reaction frequency over time.³ The catch is that medications manage what the mast cells release. They do not address what is activating them.

For environmentally-triggered MCAS, source removal is not a supplement to treatment — it is the precondition for it. Antihistamines taken while the exposure continues are fighting the fire while leaving the gas on. The clinical picture that emerges when the environmental source is identified and properly remediated is consistently different from the picture when medications are used in isolation: the food windows expand, the reaction threshold rises, the sensitivity pattern softens. Recovery is real. It is documented. And it starts with identifying every significant trigger in the patient’s environment — including those that are hidden in the walls of their home.

We Inspect’s Exposure Mapping™ process was built for exactly this gap. It identifies where active mold growth is occurring at the source level — not in the air, but in the building materials themselves — and ranks the contamination by likely exposure contribution. The result is a contractor-ready Remediation Recovery Blueprint that tells a remediation team exactly where to work and in what order. That specificity is what keeps families from spending tens of thousands on interventions that won’t meaningfully reduce exposure because they addressed the wrong locations.

Key Takeaways

• MCAS diagnosis requires serum tryptase collected within hours of a reaction, compared against a documented symptom-free baseline — a 20% + 2 ng/mL rise is the threshold. Most workups never establish the baseline.
• The most reliable markers are 24-hour urine N-methylhistamine and 11β-prostaglandin F2α. Serum histamine alone is insufficient.
• Environmental triggers — including mold and mycotoxins from water-damaged buildings — are rarely evaluated in standard MCAS workups and are a meaningful activating factor for many patients.
• Removing the environmental source, not only managing mediator release with medication, is what creates the conditions for genuine recovery.

MCAS testing is more specific than most patients realize, and more procedurally demanding than most practices are set up to handle. Knowing what to ask for — the right markers, the right timing, the right baseline protocol — gives you a real shot at a result that reflects what’s actually happening in your body. And knowing that the trigger list should include your home environment is the piece most workups leave out entirely.

Next Steps

If you want to know what your home is actually doing to your body, we can find out. We Inspect uncovers hidden mold contamination, ranks what truly drives your exposure, and delivers a contractor-ready Remediation Recovery Blueprint designed to meaningfully reduce exposure so your body can heal — without wasting tens of thousands on unnecessary fixes that won’t move the needle. Get My Free Exposure Consultation

Frequently Asked Questions

Can serum tryptase be normal and you still have MCAS?

Yes. Serum tryptase is often normal in MCAS even during active flares, because the threshold for a diagnostic elevation requires comparison against a documented baseline. If no baseline exists, a result in the normal range cannot rule out MCAS. This is why 24-hour urine markers are a critical part of the workup rather than an optional add-on.

How is MCAS different from a standard allergic reaction?

Traditional IgE-mediated allergies involve a specific antibody response to a known allergen. MCAS involves mast cell activation through multiple non-IgE pathways, often without a single identifiable allergen. This is why MCAS patients frequently test negative on standard allergy panels but continue to react broadly to foods, chemicals, temperature changes, and environmental factors.

Can mold in the home cause or worsen MCAS?

Research links mold-derived compounds, including certain mycotoxins and volatile organic compounds from water-damaged buildings, to mast cell activation in sensitized individuals. For MCAS patients who experience more symptoms at home than away, or whose symptoms worsened after a move or water damage event, the home environment warrants formal evaluation as a potential ongoing trigger.

What kind of doctor diagnoses MCAS?

MCAS is most commonly diagnosed by allergists and immunologists, though some hematologists and functional medicine physicians also manage it. Finding a practitioner familiar with the current consensus criteria — particularly the timed mediator testing protocol — significantly improves the likelihood of an accurate workup. The criteria itself are not obscure; the challenge is finding a practice prepared to collect samples correctly.

What is the first step after suspecting MCAS?

The first step is establishing a timed mediator baseline. This means a symptom-free serum tryptase draw, followed by a 24-hour urine collection for N-methylhistamine and 11β-prostaglandin F2α collected during or around a symptomatic episode. Bring a written symptom log covering frequency, duration, and organ systems involved to the first appointment. Document any pattern of symptoms that improve when away from home.

References

1. Molderings GJ, Brettner S, Homann J, Afrin LB. Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options. J Hematol Oncol. 2011;4:10. doi:10.1186/1756-8722-4-10
2. Valent P, Akin C, Bonadonna P, et al. Proposed diagnostic algorithm for patients with suspected mast cell activation syndrome. J Allergy Clin Immunol Pract. 2019;7(4):1125-1133.e1. doi:10.1016/j.jaip.2018.11.032
3. Afrin LB, Self S, Menk J, Lazarchick J. Characterization of mast cell activation syndrome. Am J Med Sci. 2017;353(3):207-215. doi:10.1016/j.amjms.2016.12.013
4. Theoharides TC, Valent P, Akin C. Mast cells, mastocytosis, and related disorders. N Engl J Med. 2015;373(2):163-172. doi:10.1056/NEJMra1409760
5. Hamilton MJ, Hornick JL, Akin C, Castells MC, Greenberger NJ. Mast cell activation syndrome: a newly recognized disorder with systemic clinical manifestations. J Allergy Clin Immunol. 2011;128(1):147-152. doi:10.1016/j.jaci.2011.04.029
6. Karnell JL, et al. Mycophenolic acid differentially impacts B cell function depending on the activation signal. J Immunol. 2011;187(6):3300-3317. doi:10.4049/jimmunol.1003319

This article is for informational purposes only and does not constitute professional medical advice. If you believe mold or other environmental hazards may be affecting your health, consult your healthcare provider.